RenovoRx (RNXT) Other Non Operating Income (2021 - 2022)
RenovoRx (RNXT) posted Other Non Operating Income of $3000.0 for Q3 2022, up 200.0% sequentially from $1000.0 in Q1 2022, and down 98.24% YoY from $170000.0 in Q3 2021.
RenovoRx (RNXT) Other Non Operating Income (2021 - 2022) Analysis & Trends
RenovoRx has reported Other Non Operating Income for 2 years, with the latest figure at $3000.0 in Q3 2022.
- Quarterly Other Non Operating Income fell 98.24% year-over-year to $3000.0 in Q3 2022, while the trailing twelve-month figure through Dec 2022 was $4000.0 (down 93.44% YoY) and the FY2022 annual result came in at $4000.0, down 93.55% from the prior year.
- Other Non Operating Income grew to $3000.0 in Q3 2022 per RNXT's latest filing, from $1000.0 in the prior quarter.
- Over five years, Other Non Operating Income peaked at $170000.0 in Q3 2021 and troughed at -$57000.0 in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | RenovoRx | 62.20 Mn | 62.20 Mn | 766,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Dec 31, 2021 | -57,000.00 |
| Sep 30, 2021 | 170,000.00 |
| Jun 30, 2021 | -47,000.00 |
| Mar 31, 2021 | -5,000.00 |